Method for treating growth hormone deficiency employing hGH fusion protein
AssigneesGenexine, Inc., Handok Inc.
InventorsTae Kyung Kim, Jung Won Woo, Joan Yoon Ji Lee, Young-Joo Ahn, Ji-Eun Cha, Hyou Young Rhim, Woo Ick Jang
Life of this patent
Estimating the term…
Abstract
A method for treating growth hormone deficiency, including administering a human growth hormone fusion protein (GX-H9). A method includes administering a pharmaceutical composition containing an hGH fusion protein (GX-H9) and a pharmaceutically acceptable carrier, wherein the fusion protein (GX-H9) is administered once a week at a dose of 0.4 to 1.6 mg per body weight kg of a pediatric patient, or administered once every two weeks at a dose of 0.8 to 3.2 mg per body weight kg of a pediatric patient.
Claims7
A method for treating growth hormone deficiency of a subject in need thereof, comprising the following step (i) or step (ii):
- (i) administering an hGH fusion protein GX-H9 to the subject once a week at a dose of 0.4 to 1.5 mg per body weight kg of the subject, or
- (ii) administering an hGH fusion protein GX-H9 to the subject once every two weeks at a dose of 0.8 to 3.0 mg per body weight kg of the subject,
- wherein the hGH fusion protein GX-H9 comprises the amino acid sequence of SEQ ID NO:
- 1;
- and
- wherein the subject is a pediatric patient.
Dependencies are inferred from the claim text.